Introduction/Background Growing teratoma syndrome (GTS) is a rare clinical condition typically characterized by paradoxical findings of having normal serum tumor markers and enlarging metastatic lesions on the clinical examination and/or imaging studies during the adjuvant chemotherapy and/or follow-up period. The histology of tumors after surgery reveals mature teratoma elements without viable germ cells. The appropriate management is complete surgical resection and is currently the standard of care. We aim to evaluate the surgical and oncological outcomes and follow up of patients with GTS.

Methodology Retrospective analysis of clinicopathological outcomes of patients undergoing treatment for GTS between 2011 and 2021. Patient demographics and clinical characteristics were calculated using descriptive analysis. Survival estimates for overall survival and disease-free survival are obtained using the Kaplan Meier method. Median follow-up is calculated using the reverse Kaplan-Meier method. OS and DFS between two or more groups are compared using the Log Rank test. A two-tailed p-value less than 0.05 was considered statistically significant.

Results A total of 32 cases were included. Around 70% were stage I/II at initial diagnosis and 60% progressed to GTS during the course of chemotherapy. Most of them presented as multiple site recurrences (78%). Surgery was done in 27 cases. Presence of residual disease at surgery for GTS and initial stage were found to be significant predictors for overall survival and time to recurrence in GTS.

Conclusion GTS is a rare entity and treatment is individualized based on several factors. A complete cytoreduction is the most important predictor for survival in these patients.

Disclosures there are no disclosures